Reuters: Health
Biogen Inc is planning to file for U.S. regulatory approval for its Alzheimer's treatment aducanumab after fresh analysis of its clinical trial showed promise, the drugmaker said on Tuesday, sending its shares up 21% before the bell.
Biogen to seek U.S. approval for Alzheimer's drug; shares jump 21%
Biogen to seek U.S. approval for Alzheimer's drug; shares jump 21%
Reuters: Health
Biogen Inc is planning to file for U.S. regulatory approval for its Alzheimer's treatment aducanumab after fresh analysis of its clinical trial showed promise, the drugmaker said on Tuesday, sending its shares up 21% before the bell.
Reuters: Health
Biogen Inc is planning to file for U.S. regulatory approval for its Alzheimer's treatment aducanumab after fresh analysis of its clinical trial showed promise, the drugmaker said on Tuesday, sending its shares up 21% before the bell.
Subscribe to:
Post Comments (Atom)
Popular Posts
|
No comments:
Post a Comment